In the disease-free interval (DFI), NUP188 played a risk role for patients with ACC, LGG, LIHC, MESO, sarcoma (SARC), SKCM, and uveal melanoma (UVM), but benefited the patients with KIRC and UCEC (Figure 3E). This evidence concerns the gene NUP188 and sarcoma.